72 results about "Therapy radiation" patented technology

Disclosed herein are systems and methods for real-time monitoring of patient position and / or location during a radiation treatment session. Images acquired of a patient during a treatment session can be used to calculate the patient's position and / or location with respect to the components of the radiation therapy system. One variation of a radiation therapy system includes a circular gantry with a rotatable ring coupled to a stationary frame, a therapeutic radiation source mounted on the rotatable ring, and a patient-monitoring imaging system mounted on the rotatable ring. The patient-monitoring system may have one or more image sensors or cameras disposed on the rotatable ring within a bore region of the radiation therapy system, and may be configured to acquire image data as the ring rotates.

A phototherapy face mask is provided for emitting therapeutic radiation towards the facial region of a user and aims to restore the youthful appearance of the user who is wearing the mask. The phototherapy mask comprises an outer surface and an inner surface, wherein the inner surface is aligned with the facial skin of the user. A flexible PCB layer is provided between the inner surface and the outer surface, on which a plurality of coherent light sources such as LEDs are mounted. The light sources are configured to emit radiation preferably in the visible and infrared range of the electromagnetic spectrum. The mask further includes a medicament chamber which is operably coupled to a piezoelectric pump that dispenses the medicament at regular intervals. The medicament is uniformly distributed all over the facial region of the user through a plurality of pores of the mask.

A controller (600) for a radiotherapy device (320) is provided; the radiotherapy device (320) being configured to provide therapeutic radiation to a patient (308) via a source (300) of therapeutic radiation, wherein the radiotherapy device (320) comprises a first rotatable member (304), the rotation of which can alter a physical attribute of the therapeutic radiation provided, and a patient support member (310), which is linearly moveable in at least one of a longitudinal direction and a lateral direction. The controller (600) comprises a first rotatable actuator (608) for controlling a movement of the first rotatable member (304) and a second actuator (620) for controlling a movement of the patient support member (310).

The invention discloses an application of nano hydrogen bubble water in preparation of a medicine for preventing or treating radiation, and discovers and verifies that the nano hydrogen bubble water has a new anti-radiation application for the first time, and can obviously prolong the lifetime of a mouse after radiation. And the compound has a more prominent effect in the aspect of treating sensitive tissue and organ injuries caused by radiation.

Disclosed herein are methods for radiotherapy treatment planning and delivery that use sensor data from one or more target sensors. One variation of a radiotherapy treatment planning method comprises generating a sensor characterization image based on a sensor characterization probability density function (PDF) of a target sensor and calculating a set of firing filters that may be applied to sensor images generated from sensor data acquired during a radiation-delivery session. Additionally, a variation of a radiotherapy treatment planning method comprises generating multiple sensor characterization images based on multiple sensor characterization PDF of multiple target sensors and calculating multiple sets of firing filters for each of the multiple target sensors. The firing filters may be used with sensor images generated from target sensor data acquired from one or more target sensors during a radiation-delivery session to calculate a radiation fluence for delivering therapeutic radiation to a target region.

Disclosed herein are methods for verifying whether a radiotherapy delivery system delivers therapeutic radiation to a target region in accordance with instructions from a radiotherapy system controller. The method utilizes imaging data acquired by a radiation imager (e.g., an MV detector) located opposite (e.g., positioned relative to) a therapeutic radiation source. In some variations, the imaging data from the radiation imager is used to determine whether a component of a radiation beam shaping assembly is in a position specified by the controller instructions. Also disclosed herein are methods for verifying whether a radiation beam emitted by the therapeutic radiation source intersects a target region and / or a contour around the target region, including methods for determining a delivery fluence and a dose estimate.

Apparatus and methods are described for treating an occlusion in a blood vessel. A catheter is inserted into the blood vessel. An irradiation unit is driven to emit probing radiation such that the probing radiation is directed toward the occlusion, and returning radiation which is returned in response to the probing radiation impacting the occlusion, is detected. A composition of at least a portion of the occlusion is derived based on a signature that is indicative of the composition within the returning radiation. The irradiation unit is driven to irradiate the portion of the occlusion by emitting treatment radiation having a set of irradiation parameters. The set of irradiation parameters is determined to modulate between a photoacoustic effect of the treatment radiation and a photothermal effect of the treatment radiation, based on the composition of the portion of the occlusion. Other applications are also described.

A therapeutic apparatus may be provided. The therapeutic apparatus may include a radiation therapy device configured to apply therapeutic radiation to a region of interest (ROI). The radiation therapy device may include an accelerator configured to accelerate electrons in an electron beam to produce a radiation beam of the therapeutic radiation, a magnetic resonance imaging (MRI) device configured to acquire MRI data with respect to the ROI. The MRI device may include an annular cryostat including at least one annular structure enclosing one or more chambers.

The invention discloses an application of fucoidin in preparation of a medicine for preventing or treating radiation-induced leucopenia. The effect of the fucoidin for preventing and treating radiation-induced leucopenia is investigated by measuring the influence of the fucoidin on the five-classification counting of peripheral blood leucocytes, thymus and spleen indexes, the number of bone marrow nucleated cells, the activity of bone marrow cells and the formation number of bone marrow cell colonies of a mouse with radiation-induced leucopenia. A test result shows that the fucoidin has a remarkable curative effect on preventing and treating radiation-induced leucopenia and has no toxic or side effect.

A radiotherapy treatment apparatus for imaging and treating a patient, comprising: a radiotherapy system comprising a treatment radiation source configured to perform radiotherapy treatment of a patient by directing treatment radiation towards the patient, wherein the patient is located substantially within a treatment region defining a longitudinal axis, wherein the treatment radiation source is moveable with respect to the longitudinal axis to thereby enable a selection of a treatment direction in preparation for radiotherapy treatment of the patient; an imaging system comprising an imaging radiation source and a radiation detector, wherein the imaging radiation source is moveable with respect to the longitudinal axis and is arranged to direct imaging radiation towards the patient in an imaging direction, and wherein the radiation detector is arranged to measure the imaging radiation after interaction of the imaging radiation with the patient, wherein the radiation detector comprises one or more photon counting detector arrays defining a sensitive area of the radiation detector, and wherein the imaging system is configured to generate multi-spectral images of the patient based on measurements of the imaging radiation by the one or more photon counting detector arrays.

The application discloses a kind of compositions for treating radiation enteropathy and application thereof, belong to medical technology field.The composition includes the following components: anemarrhena asphodeloides B4, obakunine, berberine, aesculetin, fraxinellone and fraxinellin.The composition has no toxic side effects, has good safety, can reduce the inflammatory infiltration of intestinal epithelial cells, reduce intestinal epithelial cell apoptosis, protect intestinal barrier and protect intestinal oxidative damage by regulating NF-κB, Caspase 9 / 3 and NRF2 pathway, and then multi-component, multi-pathway jointly play the efficacy of treating radiation enteropathy.The problem that there is no effective drug for treating radiation enteropathy in the prior art is solved.

In some examples, a laser-based ophthalmological surgical system (hereinafter “system”) includes a therapeutic radiation source configured to emit therapeutic radiation with a first wavelength. The system may also include a probe radiation source configured to emit probe radiation with a second wavelength different than the first wavelength. The system may also include one or more optical elements configured to direct the therapeutic radiation and the probe radiation into an eye of a patient and to collect reflected probe radiation from the eye of the patient. The reflected probe radiation may be indicative of an amount of therapeutic radiation exposure of the eye of the patient. The system may also include a photodetector configured to receive the reflected probe radiation from the one or more optical elements and to generate a photocurrent indicative of the amount of therapeutic radiation exposure of the eye of the patient.

The present invention relates to parenteral pharmaceutical compositions of suitable Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, particularly to Desidustat or suitable pharmaceutically acceptable salts thereof. The invention also relates to processes for preparing such compositions. The present invention also relates to the development of therapeutic compound for the treatment of radiation induced toxicity. Specifically, present invention relates to use of Desidustat or its pharmaceutically acceptable salt or oral and parenteral pharmaceutical composition thereof for the treatment of radiation induced toxicity.

The disclosure relates to a device for detecting therapeutic radiation based on an optical disk with solar cells. The radiation detecting device may include at least one optical disk formed of a water-equivalent material, disposed perpendicular to a first direction in which the radiation is incident, and converting the radiation into visible light; a solar cell disposed on one side of the at least one optical disk, converting the visible light into an electrical signal; and a processing module for collecting and processing the electrical signal outputted from the solar cell.

Methods, systems and apparatus are disclosed for delivery of pulsed treatment radiation by employing a pump radiation source generating picosecond pulses at a first wavelength, and a frequency-shifting resonator having a lasing medium and resonant cavity configured to receive the picosecond pulses from the pump source at the first wavelength and to emit radiation at a second wavelength in response thereto, wherein the resonant cavity of the frequency-shifting resonator has a round trip time shorter than the duration of the picosecond pulses generated by the pump radiation source. Methods, systems and apparatus are also disclosed for providing beam uniformity and a sub-harmonic resonator.

The invention relates to the technical field of ion beam irradiation treatment radiation protection, and provides a treatment room radiation shielding system and method based on a rotating beam line, and the system comprises a central equipment room which is internally provided with rotatable treatment equipment; the plurality of treatment rooms are arranged around the central equipment room, and each treatment room is used for treating a patient; the radiation shielding wall body comprises a shielding partition wall and a shielding enclosure wall, the shielding partition wall is arranged between the adjacent treatment rooms, and the shielding enclosure wall is arranged on the periphery of the treatment rooms; a radiation attenuation channel communicated with the treatment room is defined by the shielding partition wall and the shielding enclosing wall. According to the treatment room radiation shielding system based on the rotating beam wire, the radiation attenuation channel communicated with the treatment room is defined by the shielding partition wall and the shielding enclosing wall, the space utilization rate is improved, and the limited space radiation shielding problem of the treatment room is solved.

The invention discloses a product for treating radiation damage. According to the application, GP532 is subjected to random mutation, a phage mutation library is established, and the mutation library is activated and screened by using TLR5-dependent NF-kappa B, so that 9E1 is obtained. 9E1 shows dose-dependent stimulation of TLR5 dependent NF-kB activation in vitro; an effective prevention effect is shown in an in-vivo mouse radiation injury model, and a new way is provided for effective treatment of radiation injury.

The invention relates to a ganoderma lucidum fermentation product and a preparation method and application thereof, and belongs to the field of medicine and health care products. The ganoderma lucidum fermentation product is prepared from total sugar, fat, total protein, polypeptide, vitamin A, vitamin E, vitamin C and total terpenoids according to the mass ratio of (2500 to 5000) to (100 to 500) to (1500 to 3000) to (100 to 500) to (1 to 50) to (10 to 50) to (20 to 100) to (200 to 500). The ganoderma lucidum fermentation product disclosed by the invention can improve lipid oxidation caused by radiation, so that the effects of maintaining body health and the like are achieved; the compound can be used for preparing medicines or health-care products for preventing and treating radiation.

A method for determining whether a radiotherapy device should be authorized for use, the radiotherapy device being configured to provide therapeutic radiation to a patient. The radiotherapy device comprises a plurality of components, each of the plurality of components being coupled to at least one identifier, the at least one identifier being configured to provide data identifying the component coupled thereto. The method comprises: receiving data identifying each of the plurality of components of the radiotherapy device from the identifier; determining whether at least one authorization criterion is satisfied based on the identification data and the authorization data; and determining that the treatment device is authorized for use if the at least one authorization criterion is satisfied.

The present specification provides a treatment device (110, 110', 400, 400', 500, 500', 600, 600'). The treatment device (110, 110', 400, 400', 500, 500', 600, 600') may include a magnetic resonance imaging (MRI) device (310) for acquiring MRI data about a region of interest (ROI); and a radiotherapy device (300) for applying therapeutic radiation to at least a portion of the ROI. The MRI device (310) may include an annular cryostat (403, 503, 603, 700) having one or more chambers (403a, 403b, 503a, 503b, 603a, 603b), an annular structural device, and a groove (408, 508, 608) provided on the annular structural device. The radiotherapy apparatus (300) may include at least an accelerator (409, 509) and one or more collimation assemblies (412, 410, 512, 510, 612, 610).

The present application relates to a complex compound in which iron ions and zinc ions are combined, a pharmaceutical composition containing the same, and a method for preparing the same.

The present invention relates to parenteral pharmaceutical compositions of suitable Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, particularly to Desidustat or suitable pharmaceutically acceptable salts thereof. The invention also relates to processes for preparing such compositions. The present invention also relates to the development of therapeutic compound for the treatment of radiation induced toxicity. Specifically, present invention relates to use of Desidustat or its pharmaceutically acceptable salt or oral and parenteral pharmaceutical composition thereof for the treatment of radiation induced toxicity.

The present disclosure relates to an imageable microsphere comprising one or more radionuclides, and methods of making and using the same in transarterial radioembolization (TARE). The microsphere is a theranostic. The microsphere provides radionuclide imaging and emits therapeutic radiation.

The present disclosure provides compositions and methods for use in treating radiation injury such as a radiation induced skin injury in a subject at risk of such injury. Also provided herein is a reproducible animal model of cutaneous radiation injuries for evaluation of medical countermeasures.

The application discloses a kind of for radiation intestinal injury treatment composition and its application, it is related to medical technical field.The composition includes the following components: aesculetin, fraxinol, fraxin and baicalein.The composition of the application can reduce intestinal villus injury by regulating the NF-κB pathway and Caspase-9 / 3 pathway of intestinal epithelial cells, reduce the infiltration of intestinal inflammatory cells, reduce intestinal cell apoptosis, to relieve intestinal injury, and then multi-component, multi-pathway jointly play the efficacy of treating radiation intestinal injury.The application solves the problem that there is no effective drug for treating radiation intestinal injury in the prior art.

The application discloses a composition for treating radiation enteropathy and application thereof, and belongs to the technical field of biological medicine, and solves the problem that there is no effective treatment drug for radiation enteropathy at present. The composition comprises puerarin, baicalein, berberine and glycyrrhetinic acid. The composition for treating radiation enteropathy can regulate Wnt / beta-catenin, NF-kappa B and Caspase-9 / 3 signal pathways and the like, promote the proliferation of intestinal cells after radiation damage, reduce the inflammation level of intestinal tissues after radiation, reduce the apoptosis of intestinal cells after radiation and the like, improve the radiation damage of intestinal epithelial cells, play an anti-radiation enteropathy role, and has a remarkable effect on treating radiation enteropathy.

The invention discloses a human placenta-derived endothelial progenitor cell and a combined drug thereof as well as application of the human placenta-derived endothelial progenitor cell in preparation of a drug for treating radiation-induced thymus injury, and discloses a novel cell treatment drug for reconstructing a thymus microenvironment, recovering T cell generation and promoting thymus function repair and immune reconstruction aiming at thymus radiation injury. The placenta-derived endothelial progenitor cells are found to have an excellent effect of treating the radiation thymus injury, and the human placenta-derived endothelial progenitor cells and the human umbilical cord mesenchymal stem cells are synergistically combined to have a synergistic effect on treating the radiation thymus injury.

The present invention relates to a method and apparatus for multi-criteria optimization of radiation therapy plans. A control circuit accesses an optimized radiation therapy plan developed using corresponding utility functions corresponding to a plurality of metrics, and generates an approximation of the corresponding utility functions. The control circuit repeatedly selectively perturbs the approximation only with respect to a different subset of the plurality of metrics each time to generate a corresponding plurality of perturbed utility functions, and generates a plurality of supplemental optimized radiation therapy plans each time from a corresponding different one of the plurality of perturbed utility functions. The control circuit then employs the plurality of supplemental optimized radiation therapy plans and the optimized radiation therapy plan as a multi-criteria optimization workspace for a user to explore in selecting a particular optimized radiation therapy plan for employment in administering therapeutic radiation to a particular patient.

A method of determining whether repair or replacement of a radiotherapy device thyratron should be scheduled where the device comprises a linear accelerator for providing therapeutic radiation to a pa

The present invention relates to the technical field of radiation measurement in radiotherapy. The purpose is to be applicable to different X-ray radiation measurement scenarios through design. A flexible X-ray radiotherapy radiation dose measurement device is disclosed, which includes flexible protective layers arranged on both sides to support and protect the internal structure. Between the two flexible protective layers, there is a flexible radiation detection unit responsible for converting radiation into an electrical signal, and a flexible readout circuit for reading out the electrical signal generated by the flexible radiation detection unit. The flexible radiation detection unit includes a flexible scintillator material layer and a flexible photoelectric conversion layer. By adopting a flexible structure in the detector, the present invention has the characteristic of being flexibly deformable, enabling the detector to fit the human body surface and improving comfort. By adopting a plastic material in the support structure, the present invention has a memory characteristic, enabling the detector to conform to the human body and improving repeatability.